Asgari Z, Moini A, Samiee H, Tehranian A, Mozafar-Jalali S, Sabet S. Endometrial ablation with the NovaSure system in Iran.
Int J Gynaecol Obstet 2011;
114:73-5. [PMID:
21507403 DOI:
10.1016/j.ijgo.2010.12.023]
[Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2010] [Revised: 12/11/2010] [Accepted: 03/22/2011] [Indexed: 11/24/2022]
Abstract
OBJECTIVE
To evaluate the rate of response to treatment with the NovaSure endometrial ablation device among Iranian women with menorrhagia.
METHODS
Twenty 35-50-year-old women with menorrhagia who were referred to Arash Hospital, Tehran, Iran, in 2008 were enrolled. They underwent endometrial ablation via the NovaSure system and were followed-up for 2 years.
RESULTS
The incidence of amenorrhea was 30.0% at the end of the 2-year follow-up period. Hypomenorrhea was reported by 40.0% of women. The mean number of days of bleeding per month decreased significantly, from 30.0 ± 6.4 days before treatment to 3.1 ± 2.6 days after 2 years (P < 0.001). The severity of bleeding decreased significantly within 2 years after treatment (P < 0.001). In total, 85.0% of women were satisfied and 90.0% had responded to treatment-as defined by amenorrhea, hypomenorrhea, or return to normal menstruation.
CONCLUSION
The NovaSure system is effective and should be considered by gynecologists for the treatment of menorrhagia.
Collapse